Pfizer (NYSE:PFE) Sets New 1-Year High – Should You Buy?

Pfizer Inc. (NYSE:PFE) shares hit a new 52-week high during trading on Tuesday. The company traded as high as $30.15 and last traded at $30.0580, with a volume of 4,905,624 shares trading hands. The stock had previously closed at $29.44.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Healthcare-sector rotation is supporting PFE. Biotech and pharmaceutical stocks have held up relatively well as investors reduce exposure to technology and AI shares. Pfizer is being viewed as a value-and-income turnaround, with a forward P/E near 10 and a dividend yield around 5.8%. The Market Is Selling Off. Biotech and Pharma Aren’t.
• Positive Sentiment: Investors are responding to Pfizer’s turnaround narrative. Recent cancer-related approvals, an oncology alliance and expectations for portfolio improvements have strengthened the case that Pfizer can offset the decline in pandemic-era products. The stock has delivered a strong year-to-date return and is trading near its annual high. What Pfizer Bulls Got Right
• Neutral Sentiment: Analyst sentiment remains cautious. Wells Fargo and RBC Capital have maintained Hold ratings, indicating that Pfizer’s valuation and dividend are attractive but that the company still needs to demonstrate sustainable earnings growth. Pfizer Gets a Hold from Wells Fargo
• Neutral Sentiment: Elranatamab clinical progress is a potential pipeline catalyst. Pfizer has completed its Phase 2 MAGNETISMM-3 study, but the investment impact will depend on detailed results, regulatory progress and the drug’s commercial potential. Pfizer’s Elranatamab Trial Update
• Negative Sentiment: Dividend sustainability remains a concern. Commentary questioning whether Pfizer’s cash generation comfortably covers its dividend could limit enthusiasm for the stock, particularly while non-oncology revenue, vaccine demand and pricing trends remain important risks heading into the next quarterly report. Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. HSBC boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. BMO Capital Markets reduced their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.72.

Pfizer Stock Up 2.1%

The firm has a market cap of $171.36 billion, a price-to-earnings ratio of 39.49, a PEG ratio of 2.01 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The business’s 50-day moving average is $28.05 and its 200-day moving average is $26.57.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.7%. Pfizer’s payout ratio is 226.32%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Retirement Wealth Solutions LLC raised its position in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 509 shares during the last quarter. Evolution Wealth Management Inc. grew its holdings in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the last quarter. Keb Asset Management LLC bought a new stake in shares of Pfizer during the second quarter worth $26,000. Field & Main Bank acquired a new stake in shares of Pfizer in the second quarter valued at $27,000. Finally, Global Trust Asset Management LLC increased its stake in shares of Pfizer by 126.7% in the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 650 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.